Results 211 to 220 of about 11,649,511 (362)
Report on the Action of Drugs on the Leucocytes of the Blood [PDF]
, 1896 G. Wilkinson
openalex +1 more source
Trends in GPCR drug discovery: new agents, targets and indications
Nature reviews. Drug discovery, 2017 A. Hauser +4 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga +8 more
wiley +1 more source
Potential drug-drug interactions among hospitalised cardiac patients in Nepal: a prospective observational study. [PDF]
BMJ OpenSah BK +5 more
europepmc +1 more source
YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma
Molecular Oncology, EarlyView.The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy +9 more
wiley +1 more source
Literature data-based de novo candidates for drug repurposing. [PDF]
BMC BioinformaticsLiang X, Jiang X, Ma Y.
europepmc +1 more source
The Determination of Sulphurous Acid in Gelatine: A Manufacturer's Position with Regard to the Food and Drugs Act. [PDF]
, 1907 Jerome Alexander
openalex +1 more source
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.
Advanced Drug Delivery Reviews, 2016 J. S. Suk +4 more
semanticscholar +1 more source